Literature DB >> 11425415

Pharmacopoeial quality of drugs supplied by Nigerian pharmacies.

R B Taylor1, O Shakoor, R H Behrens, M Everard, A S Low, J Wangboonskul, R G Reid, J A Kolawole.   

Abstract

BACKGROUND: The quality of medicines available in some less-developed countries is inadequate in terms of content of active ingredient. Reasons for the poor quality of drugs include widespread counterfeiting of medicines in less-developed countries, excessive decomposition of active ingredient as a result of high temperature and humidity, and poor quality assurance during the manufacture of medicinal products. Our aim was to investigate the quality of different drugs obtained from retail pharmacies in two urban areas of Nigeria, and, in instances of poor quality, to ascertain the reason why.
METHODS: We randomly collected 581 samples of 27 different drugs from 35 pharmacies in Lagos and Abuja in Nigeria. We analysed the medicines for drug content by validated chromatographic methods, and compared our results with pharmacopoeial requirements.
FINDINGS: 279 (48%) samples did not comply with set pharmacopoeial limits, and this proportion was uniform for the various types of drugs tested. Although some preparations contained no active ingredient, most had amounts just outside the pharmacopoeial limits. We identified samples with both too much and too little active drug content.
INTERPRETATION: The most probable cause of the poor quality of drugs is absence of adequate quality assurance during manufacture. Substandard drugs sold in the pharmacies of less-developed countries could contribute to global microbial resistance and therapeutic failure of infectious diseases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11425415     DOI: 10.1016/s0140-6736(00)05065-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  49 in total

1.  Murder by fake drugs.

Authors:  Paul N Newton; Nicholas J White; Jan A Rozendaal; Michael D Green
Journal:  BMJ       Date:  2002-04-06

2.  Therapeutic efficacy of linezolid in extended clinical practice.

Authors:  S C Arya
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-02-15       Impact factor: 3.267

3.  Anti-malarial drug quality in Lagos and Accra - a comparison of various quality assessments.

Authors:  Roger Bate; Kimberly Hess
Journal:  Malar J       Date:  2010-06-11       Impact factor: 2.979

Review 4.  Pharmacological treatment of severe psychiatric disorders in the developing world : lessons from India.

Authors:  Vikram Patel; Chittaranjan Andrade
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 5.  Therapy of falciparum malaria in sub-saharan Africa: from molecule to policy.

Authors:  Peter Winstanley; Stephen Ward; Robert Snow; Alasdair Breckenridge
Journal:  Clin Microbiol Rev       Date:  2004-07       Impact factor: 26.132

6.  Evolution of Rifampin Resistance in Escherichia coli and Mycobacterium smegmatis Due to Substandard Drugs.

Authors:  Zohar B Weinstein; Muhammad H Zaman
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

7.  The quality of drugs in private pharmacies in Lao PDR: a repeat study in 1997 and 1999.

Authors:  Lamphone Syhakhang; Cecilia Stålsby Lundborg; Björn Lindgren; Göran Tomson
Journal:  Pharm World Sci       Date:  2004-12

Review 8.  Antimalarial drug quality in Africa.

Authors:  A A Amin; G O Kokwaro
Journal:  J Clin Pharm Ther       Date:  2007-10       Impact factor: 2.512

9.  A stratified random survey of the proportion of poor quality oral artesunate sold at medicine outlets in the Lao PDR - implications for therapeutic failure and drug resistance.

Authors:  Sivong Sengaloundeth; Michael D Green; Facundo M Fernández; Ot Manolin; Khamlieng Phommavong; Vongsavanh Insixiengmay; Christina Y Hampton; Leonard Nyadong; Dallas C Mildenhall; Dana Hostetler; Lamphet Khounsaknalath; Latsamy Vongsack; Samlane Phompida; Viengxay Vanisaveth; Lamphone Syhakhang; Paul N Newton
Journal:  Malar J       Date:  2009-07-28       Impact factor: 2.979

10.  Impact of poor-quality medicines in the 'developing' world.

Authors:  Paul N Newton; Michael D Green; Facundo M Fernández
Journal:  Trends Pharmacol Sci       Date:  2010-02-01       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.